Latest total liabilities for CANF: $3.9M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
The latest total liabilities for CANF is $3.9M as of December 2025. That compares with $3.7M in the prior-year period — up 6.5% year over year. Investors often review this figure alongside Can-Fite Biopharma's historical trend and sector peers before judging valuation or financial health.
Over the past year, CANF's total liabilities moved from $3.7M to $3.9M — a 6.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Can-Fite Biopharma's operating scale or balance-sheet position.
A total liabilities figure of $3.9M for CANF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.
After noting CANF's total liabilities ($3.9M), review year-over-year change from $3.7M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Can-Fite Biopharma's total liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.